Literature DB >> 15776568

The antigenic and molecular alterations of C3 in the fluid phase during an immune reaction in normal human serum. Demonstration of a new conversion product, C3x.

R E Spitzer, A E Stitzel, V L Pauling, N C Davis, C D West.   

Abstract

During the reaction of an immune precipitate with fresh human serum, C3 undergoes a number of molecular alterations with the formation of conversion products differing from those obtained when purified components react. Those products which remain in the fluid phase, the subject of the present paper, have been identified by their reaction with monospecific antisera to the three antigenic determinants of C3, A, B, and D, after electrophoresis in agar or polyacrylamide gel. When purified C3 reacts with EAC1,4,2, C3i is found in the fluid phase. C3i, a loose complex of C3a and C3b, is in a conformational state whereby only the A and D antigens, present on its C3b portion, will consume antibody. The B antigen, present on the C3a portion of C3i, is unavailable for combination with antibody until C3i dissociates. In the fluid phase of the reaction of an immune precipitate with whole serum, C3i, C3a, and C3b, formed when purified components react, cannot be found. Instead the end products of the reaction appear to be C3c, which contains the A antigen, and C3d, which contains the D antigen. C3c and C3d are similar to the beta1A and alpha2D produced by the aging of serum but differ in their mobilities in acrylamide gel and in agar. The C3c and C3d generated by an immune precipitate also differ slightly from the C3c and C3d produced by the reaction of trypsin with C3 in whole human serum. As human serum reacts with an immune complex, native C3 appears to undergo a primary alteration before conversion. This alteration results in a molecular species of C3 which is labile at 56 degrees C for 30 min, fails to expose additional A and D antigenic sites upon aging, and which forms beta1A and C3d rather than beta1A and alpha2D during aging. In addition to this altered form of native C3, a new conversion product, C3x, is formed as whole serum reacts with an immune complex. C3x is not found in systems utilizing pure complement components. C3x is like C3 in that it bears all three antigenic determinants but differs in that it has a slightly faster mobility in polyacrylamide gel than does native C3. C3x is not only found in the fluid phase but is also bound to the immune precipitate. Finally, the fluid-phase kinetics of each of the antigens of C3 have been determined as normal human serum reacts with an immune precipitate. These illustrate that nearly the entire population of native C3 molecules undergoes conversion rapidly as manifested by the disappearance of the B antigen from the fluid phase. Moreover, the kinetics of the fluid-phase A and D antigens reflect that the conversion of C3 in serum is quantitatively not the same as when purified C3 reacts with C4,2.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 15776568      PMCID: PMC2139058          DOI: 10.1084/jem.134.3.656

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  19 in total

1.  DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS.

Authors:  B J DAVIS
Journal:  Ann N Y Acad Sci       Date:  1964-12-28       Impact factor: 5.691

2.  Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3.

Authors:  I Gigli; R A Nelson
Journal:  Exp Cell Res       Date:  1968-07       Impact factor: 3.905

3.  Physico-chemical characteristics of the third and fourth component of complement after dissociation from complement-cell complexes.

Authors:  A P Dalmasso; H J Müller-Eberhard
Journal:  Immunology       Date:  1967-09       Impact factor: 7.397

4.  Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.

Authors:  R A Nelson; J Jensen; I Gigli; N Tamura
Journal:  Immunochemistry       Date:  1966-03

5.  Antibodies to salivary duct cells, and other autoantibodies, in patients with Sjögren's syndrome and other idiopathic autoimmune diseases.

Authors:  T E Feltkamp; A L van Rossum
Journal:  Clin Exp Immunol       Date:  1968-01       Impact factor: 4.330

6.  Anaphylatoxin release from the third component of human complement by hydroxylamine.

Authors:  D B Budzko; H Müller-Eberhard
Journal:  Science       Date:  1969-08-01       Impact factor: 47.728

7.  Complement as a mediator of inflammation. 3. Purification of the activity with anaphylatoxin properties generated by interaction of the first four components of complement and its identification as a cleavage product of C'3.

Authors:  W D da Silva; J W Eisele; I H Lepow
Journal:  J Exp Med       Date:  1967-12-01       Impact factor: 14.307

8.  Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement.

Authors:  H J Müller-Eberhard; M J Polley; M A Calcott
Journal:  J Exp Med       Date:  1967-02-01       Impact factor: 14.307

9.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

10.  Isolation and characterization of two beta1-glycoproteins of human serum.

Authors:  H J MULLER-EBERHARD; U NILSSON; T ARONSSON
Journal:  J Exp Med       Date:  1960-02-01       Impact factor: 14.307

View more
  4 in total

1.  Human lymphocyte complement receptors. Quantitative requirements for C3 of normal and chronic lymphocyte leukemia lymphocytes.

Authors:  G L Logue; H J Cohen
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

2.  Three rat monoclonal antibodies to human C3.

Authors:  P J Lachmann; R G Oldroyd; C Milstein; B W Wright
Journal:  Immunology       Date:  1980-11       Impact factor: 7.397

3.  Contribution of humoral and cellular factors to the resistance to experimental infection by Pseudomonas aeruginosa in mice. II. Opsonic, agglutinative, and protective capacities of immunoglobulin G anti-Pseudomonas antibodies.

Authors:  A B Bjornson; J G Michael
Journal:  Infect Immun       Date:  1972-05       Impact factor: 3.441

4.  The opsonic fragment of the third component of human complement (C3).

Authors:  T P Stossel; R J Field; J D Gitlin; C A Alper; F S Rosen
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.